Company Overview and News

54
As Kim visits China, Xi flaunts bargaining chip in trade dispute

13h theedgemarkets
BEIJING (June 20): As if on cue, Kim Jong Un returned to Beijing on Tuesday in an illustration of how President Donald Trump’s tariff threats against China could spiral into a broader conflict between the world’s two largest economies.
0753 AICAF AIRC BOE AIRYY BA

54
As Kim visits China, Xi flaunts trade bargaining chip

13h japantimes.co.jp
BEIJING – As if on cue, Kim Jong Un returned to Beijing on Tuesday in an illustration of how U.S. President Donald Trump’s tariff threats against China could spiral into a broader conflict between the world’s two largest economies.
0753 AICAF AIRC BOE AIRYY BA

0
North Korea lauds, and basks in, Kim’s summit performance

2018-06-13 newsinfo.inquirer.net
A North Korean woman shows her smartphone which displays an image of meeting between North Korean leader Kim Jong Un and U.S. President Donald Trump on state media, in Pyongyang, North Korea Wednesday, June 13, 2018. The series of photos on the front page of the ruling workers’ party newspaper showed something North Koreans never would have imagined just months ago, their leader Kim warmly shaking hands with Trump.
0753 AICAF AIRC AIRYY

0
China urges 'full denuclearisation' as Kim-Trump meet

2018-06-12 channelnewsasia
BEIJING: China on Tuesday (Jun 12) praised the summit between US President Donald Trump and North Korean leader Kim Jong Un as historic and called for "full denuclearisation" to resolve tensions on the Korean peninsula.
0753 AICAF AIRC AIRYY

0
China urges ‘full denuclearization’ as Kim-Trump meet

2018-06-12 newsinfo.inquirer.net
This Wednesday, May 23, 2018 satellite file image provided by DigitalGlobe, shows the Punggye-ri test site in North Korea. North Korea has carried out what it says is the demolition of its nuclear test site in the presence of foreign journalists. The demolition happened Thursday, May 24, 2018, at the site deep in the mountains of the North’s sparsely populated northeast. The planned closing was previously announced by leader Kim Jong Un ahead of his planned summit with US President Donald Trump on June 12, 2018.
0753 AICAF AIRC AIRYY

0
Kim's wingman: Air China flight shows Beijing's influence

2018-06-11 channelnewsasia
BEIJING: When North Korean leader Kim Jong Un hitched a ride on an Air China plane to his summit with Donald Trump in Singapore, the signal was clear: Beijing remains Pyongyang's diplomatic wingman.
0753 AICAF AIRC AIRYY

0
North Korea Gets First Big Dose of Trump Summit News

2018-06-11 thenationalherald
Commuters read the news of North Korean leader Kim Jong Un’s arrival in Singapore ahead of his summit with President Donald Trump at a Pyongyang subway station in Pyongyang, North Korea Monday June 11, 2018. (AP Photo/Eric Talmadge)
0753 AICAF AIRC AIRYY

0
Here's how global financial markets may react if the North Korea summit is a success... or failure

2018-06-11 cnbc
A successful outcome of U.S. talks with North Korea could give a boost to Chinese stocks and a U.S. exchange-traded fund that tracks them, according to a historical study looking at financial market reactions to past milestones regarding the rogue nation. A disappointing outcome could hurt European stocks, the study showed.
0753 AICAF AIRC AIRYY

0
Singapore summit is only Kim Jong Un’s 4th trip abroad

2018-06-11 newsinfo.inquirer.net
Onlookers lining Orchard Road to catch a glimpse of North Korean leader Kim Jong Un’s vehicle convoy as it travelled past Ion Orchard mall on its way to the Istana, where he met Prime Minister Lee Hsien Loong yesterday. The Straits Times / Asia News Network / MARK CHEONG
0753 AICAF AIRC AIRYY

0
How North Korean state media are covering Trump-Kim summit - Channel NewsAsia

2018-06-11 channelnewsasia
SINGAPORE: State media in North Korea on Monday (Jun 11) covered Kim Jong Un’s arrival in Singapore in a news bulletin.
0753 AICAF AIRC AIRYY

0
Trump and Kim will discuss peace, denuclearisation: North Korean state media - Channel NewsAsia

2018-06-11 channelnewsasia
SEOUL: North Korea's leader Kim Jong Un and US President Donald Trump will discuss a "permanent and durable peace-keeping mechanism" and the denuclearisation of the Korean Peninsula when they meet on Tuesday, North Korean state media said Monday (Jun 11).
0753 AICAF AIRC AIRYY

0
Trump, Kim arrive for US-N. Korea summit

2018-06-10 yahoo
Singapore (AFP) - North Korean leader Kim Jong Un and Donald Trump arrived in Singapore Sunday for an unprecedented summit, with Pyongyang's nuclear arsenal at the top of the agenda and the US president calling it a "one-time shot" at peace.
0753 AICAF AIRC AIRYY

0
N. Korea's Kim arrives in Singapore for historic Trump summit

2018-06-10 sg.news.yahoo
North Korean leader Kim Jong Un arrived in Singapore Sunday for an unprecedented summit with Donald Trump, an attempt to address the last festering legacy of the Cold War, with the US president calling it a "one time shot" at peace.
0753 AICAF AIRC AIRYY

13
$12.9 Billion Airport Puts China's Biggest Airlines in a Battle for Dominance - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ZNH AICAF C6L AAL CHEAF AIRYY DLAKF SINGY UAL CEA 0694 0670 1055 0753 AIRC DLAKY DAL SINGF

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...